Two more approvals for AirFluSal Forspiro

According to Sandoz, Ireland and the Czech Republic have approved marketing applications for the AirFluSal Forspiro salmeterol/fluticasone DPI in 50-250 and 50-500 µg dosage forms for the treatment of asthma and/or COPD. The Czech approval triggers a €1.5 million milestone payment from Sandoz to Vectura. Sandoz Head of Global Respiratory Jan-Torsten Tews said, “We look . . . Read more

GSK Australia to add Ventolin nebules production capacity

GSK Australia has announced that it plans to invest AUD31 million in blow-fill-seal equipment for the manufacture of Venolin salbutamol nebules at its facility in Boronia, a suburb of Melbourne. The company cited increasing demand for asthma treatments from Turkey, Brazil, and China as the reason for the retrofit. The Boronia site is GSK’s largest . . . Read more

Catalent acquires Micron Technologies

CDMO Catalent has announced its acquisition of particle size reduction specialist Micron Technologies, which offers micronization, milling, and particle characterization services for pharmaceutical products, including inhalation powders. Catalent notes that it offers development through to commercial manufacturing for inhaled products, including potent compounds. In March 2013, Micron Technologies announced that it had been acquired by . . . Read more